Medi-Flex Inks Deal with Novation for ChloraPrep One-Step

Article

OVERLAND PARK, Kan. -- Medi-Flex, Inc., announced today it has entered into an agreement with Novation for the ChloraPrep One-Step line of patient preoperative skin preparation products. Novation, the supply company of VHA Inc. and the University Health-System Consortium (UHC), will add the four ChloraPrep product applicators to their contract portfolio beginning Sept. 1, 2003.

"Our agreement with Novation and their hospital customers will provide thousands of patients access to ChloraPrep," said Lyle Clayton, president and chief operating officer of Medi-Flex. "ChloraPrep can help hospitals reduce infections, save lives and significantly reduce healthcare costs."

ChloraPrep is the only FDA-approved 2 percent w/v chlorhexidine gluconate and 70 percent v/v isopropyl alcohol formulation available in the United States. Currently, the CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections, published in August 2002, state a preference for a 2 percent chlorhexidine-based antiseptic solution over other antiseptic agents for preparation of the skin prior to catheter insertion and site maintenance.

Studies show that ChloraPrep is effective in killing a broad spectrum of microorganisms on the skin. ChloraPrep continues killing bacteria far longer than other commonly used skin antiseptics. A single 60-second application of ChloraPrep is persistent in killing bacteria for more than 48 hours.

ChloraPrep is available in 0.67-mL Sepp, 1.5-mL Frepp, 3.0-mL and 10.5-mL applicators.

Source:Medi-Flex, Inc.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
COVID-19 infection (Adobe Stock327378972 by rost9)
3D illustration bacterium Mycobacterium tuberculosis inside human body.  (Adobe Stock 1394293997 by Tichila)
Brenna Doran, PhD, MA, who specializes in hospital epidemiology and infection prevention at the University of California, San Francisco, and is a coach and consultant in infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control at Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, PhD, RN, CIC, an associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio.
© 2025 MJH Life Sciences

All rights reserved.